Prosecution Insights
Last updated: August 14, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
5
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (17%)
4
Medium (67%)
1
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (17%)
Double-patenting + other4 (67%)
Multi-statute (no §101)1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PUTTLITZ, KARL J 2 69.1% +18.5%
AULAKH, CHARANJIT 1 80.8% -15.2%
CUNNINGCHEN, KATHLEEN MARY 1 60.4% +64.8%
HAM, JIEUN 1 50.0% +62.5%
SKOKO III, JOHN JOSEPH 1 53.2% +57.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18715609 METHOD FOR PREPARING DRUG-LINKER CONJUGATE AULAKH, CHARANJIT

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18155650 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SKOKO III, JOHN JOSEPH 14d
18532359 COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER CUNNINGCHEN, KATHLEEN MARY
18549459 METHOD FOR TREATING CANCER BY USING ANTIBODY-DRUG CONJUGATE AND USE HAM, JIEUN
18324511 ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PUTTLITZ, KARL J
17471653 ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF PUTTLITZ, KARL J

Top Art Units

Art UnitApps
1643 2
1646 2
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18715609 METHOD FOR PREPARING DRUG-LINKER CONJUGATE AULAKH, CHARANJIT 1621 §102§103§112 Non-Final OA Pending May 31, 2024
18532359 COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER CUNNINGCHEN, KATHLEEN MARY §103§112DP Non-Final OA Pending Dec 07, 2023
18549459 METHOD FOR TREATING CANCER BY USING ANTIBODY-DRUG CONJUGATE AND USE HAM, JIEUN 1643 §102§103§112DP Non-Final OA Pending Sep 07, 2023
18324511 ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PUTTLITZ, KARL J 1646 §103§112DPOther Non-Final OA Pending May 26, 2023
18155650 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SKOKO III, JOHN JOSEPH 1643 §103§112DP Non-Final OA 14d Pending Jan 17, 2023
17471653 ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF PUTTLITZ, KARL J 1646 DP Final Rejection Pending Sep 10, 2021

Managing Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month